Therapeutic options in cutaneous melanoma: latest developments.
about
Tumor cell lysates as immunogenic sources for cancer vaccine designMultiple metastatic malignant melanoma presenting intraluminal gallbladder bleeding.Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligoB7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.
P2860
Therapeutic options in cutaneous melanoma: latest developments.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Therapeutic options in cutaneous melanoma: latest developments.
@ast
Therapeutic options in cutaneous melanoma: latest developments.
@en
type
label
Therapeutic options in cutaneous melanoma: latest developments.
@ast
Therapeutic options in cutaneous melanoma: latest developments.
@en
prefLabel
Therapeutic options in cutaneous melanoma: latest developments.
@ast
Therapeutic options in cutaneous melanoma: latest developments.
@en
P2093
P2860
P356
P1476
Therapeutic options in cutaneous melanoma: latest developments.
@en
P2093
Karl D Lewis
Rene Gonzalez
Rodabe N Amaria
P2860
P304
P356
10.1177/1758834011415308
P577
2011-09-01T00:00:00Z